Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
The Penland Foundation currently has 4 pending office actions distributed within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 4 distinct examiners, which indicates that each pending matter is being handled by a different individual. Despite the variety of examiners, the work is contained within 2 distinct art units, suggesting some level of thematic grouping at the patent office.
BORGEEST, CHRISTINA M is identified as the busiest examiner for this portfolio, although she is responsible for only 1 busiest examiner pending office action. This highlights an even distribution of the 4 pending office actions among the 4 distinct examiners. Practitioners working in the Biotechnology & Pharmaceuticals sector for this entity must prepare for 4 separate examiner perspectives across the 2 distinct art units involved.
The concentration of 4 pending office actions within 2 distinct art units suggests that while the examiners differ, the technical focus remains relatively narrow. With 4 distinct examiners managing the 4 pending office actions, there is no single point of contact for the majority of the portfolio. This structure requires managing individual prosecution timelines simultaneously within the Biotechnology & Pharmaceuticals space.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAGUIO FRISING, MICHELLE F | 1 | 71.1% | +39.3% |
| BORGEEST, CHRISTINA M | 1 | 55.6% | +21.4% |
| GREENE, IVAN A | 1 | 18.7% | +6.4% |
| CURRENS, GRANT CARSON | 1 | 54.6% | +62.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392640 | TREATMENT OF DELIRIUM USING NITROUS OXIDE | GREENE, IVAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17987653 | TREATMENT OF CARDIAC ARRHYTHMIA USING BOTULINUM TOXIN | CURRENS, GRANT CARSON | 31d overdue |
| 18392662 | TREATMENT OF ACUTE HEART FAILURE USING NITROUS OXIDE AND CHRONIC HEART FAILURE USING BOTULINUM TOXIN | PAGUIO FRISING, MICHELLE F | 21d |
| 18392612 | TREATMENT OF THE DEMENTIAS USING BOTULINUM TOXIN | BORGEEST, CHRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1651 | 2 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18392662 | TREATMENT OF ACUTE HEART FAILURE USING NITROUS OXIDE AND CHRONIC HEART FAILURE USING BOTULINUM TOXIN | PAGUIO FRISING, MICHELLE F | 1651 | §103Other | Final Rejection | 21d | Pending | Dec 21, 2023 |
| 18392612 | TREATMENT OF THE DEMENTIAS USING BOTULINUM TOXIN | BORGEEST, CHRISTINA M | — | §112 | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18392640 | TREATMENT OF DELIRIUM USING NITROUS OXIDE | GREENE, IVAN A | 1619 | §103§112 | Final Rejection | — | Pending | Dec 21, 2023 |
| 17987653 | TREATMENT OF CARDIAC ARRHYTHMIA USING BOTULINUM TOXIN | CURRENS, GRANT CARSON | 1651 | §112DP | Final Rejection | 31d overdue | Pending | Nov 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial